A Phase 1 interventional study of [14C] D-1553 in Mass Balance Study, sponsored by InventisBio Co., Ltd. Completed at 1 site in China. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-01.
Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary Objectives:
Secondary Objectives:
InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm study
Drug: [14C] D-1553
\[14C\] D-1553 (approximately 400 mg/80 μCi)
The radioactivity will be determined by a liquid scintillation counter. Analyze the total recovery (that is the ratio of the radioactivity in excrement samples to the radioactivity of the drug that administered ) in excrement
Recovery and cumulative recovery of total radioactive substance in excrement (urine and feces)
Time frame: 2 weeks
Percentage of unchanged drug and its metabolites in plasma, urine and feces to the administered dose
Exposure in plasma; percentage of unchanged drug and its metabolites in urine and feces to the administered dose; identification of major metabolites in plasma, urine and feces
Time frame: 2 weeks
whole blood/plasma ratio for TRA (total radioactivity) concentration at different time points
whole blood/plasma ratio for TRA concentration at different time points
Time frame: 2 weeks
Tmax (time to maximum observed concentration) parameters of TRA;
Tmax parameters of TRA in plasma
Time frame: baseline to 2 weeks
t1/2 (terminal elimination half-life) parameters of TRA;
t1/2 parameters of TRA in plasma
Time frame: baseline to 2 weeks
Cmax (maximum concentration) parameters of TRA;
Cmax parameters of TRA in plasma
Time frame: baseline to 2 weeks
MRT (mean residence time) parameters of TRA;
MRT parameters of TRA in plasma
Time frame: baseline to 2 weeks
AUC (area under curve) parameters of TRA;
AUC parameters of TRA in plasma
Time frame: baseline to 2 weeks
Incidence and severity of AEs based on NCI CTCAE V5.0
Incidence and severity of adverse events (AEs) graded based on NCI CTCAE V5.0
Time frame: baseline to 3 weeks
Incidence and severity of SAEs based on NCI CTCAE V5.0
Incidence and severity of serious adverse events (SAEs) graded based on NCI CTCAE V5.0
Time frame: baseline to 3 weeks
Tmax parameters of D-1553 and its metabolites
Tmax parameters of D-1553 and its metabolites (if applicable) in plasma
Time frame: baseline to 2 weeks
Cmax parameters of D-1553 and its metabolites
Cmax parameters of D-1553 and its metabolites (if applicable) in plasma
Time frame: baseline to 2 weeks
AUC0-t parameters of D-1553 and its metabolites
AUC0-t parameters of D-1553 and its metabolites (if applicable) in plasma
Time frame: baseline to 2 weeks
T1/2 parameters of D-1553 and its metabolites
T1/2 parameters of D-1553 and its metabolites (if applicable) in plasma
Time frame: baseline to 2 weeks
MRT parameters of D-1553 and its metabolites
MRT parameters of D-1553 and its metabolites (if applicable) in plasma
Time frame: baseline to 2 weeks
CL/F (apparent clearance) parameters of D-1553 and its metabolites
CL/F parameters of D-1553 and its metabolites (if applicable) in plasma
Time frame: baseline to 2 weeks
Vz/F (apparent volume of distribution) parameters of D-1553 and its metabolites
Vz/F parameters of D-1553 and its metabolites (if applicable) in plasma
Time frame: baseline to 2 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in Jan 2024, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garsorasib